Neuigkeiten

CryoCath to Present at Canaccord Adams Cardiovascular Conference

Montreal, November 9, 2007 - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that Jan Keltjens, President and CEO of CryoCath, will present at the Canaccord Adams Cardiovascular Conference at the Waldorf Astoria in New York City on Tuesday, November 13 at 11:45 am ET. Mr. Keltjens will present on the Company’s market outlook and discuss some recent events and upcoming milestones, including the STOP AF IDE Trial for Arctic Front®, the Company’s minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal atrial fibrillation.

A live webcast of CryoCath’s presentation will be available at www.cryocath.com.

About Medtronic CryoCath

CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.

For further information, please contact:

Ross Marshall
Phone: 416 815 0700 ext. 238
E-mail: rmarshall@equicomgroup.com